Startup profile for Nautilus Biotechnology: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Nautilus Biotechnology funding, valuation and investors

Single-molecule proteomics platform—public via SPAC merger June 2021 (NASDAQ: NAUT).

Keep track of Nautilus Biotechnology

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

Not fully disclosed · 2018

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

public

public · Seattle, Washington

Investors in latest funding

Lead: Andreessen Horowitz

Latest tracked event: SPAC merger (NASDAQ: NAUT) (June 2021). It is shown separately because it is not counted as disclosed equity funding.

Sources: latest funding Last verified: 2026-07-25

Overview

Nautilus Biotechnology, co-founded by Sujal Patel (Isilon founder) and Dr. Parag Mallick, is developing a single-molecule proteomics platform intended to measure the human proteome at scale for research and diagnostics. Andreessen Horowitz led the company's Series A and joined the board per a16z announcement. In June 2021, Nautilus merged with A SPAC (ARYA Sciences Acquisition Corp III) and began trading on NASDAQ under ticker NAUT, raising approximately $345 million in gross proceeds per company investor relations materials. The company remains in development stage for its proteomics hardware and software stack with public reporting obligations.

Why Nautilus Biotechnology is interesting

Isilon founder Sujal Patel and Stanford's Parag Mallick aim to quantify the proteome at single-molecule resolution; a16z led Series A and joined the board before ~$345M SPAC gross proceeds.

Product & use cases

Nautilus builds proteomics instrumentation analyzing individual protein molecules—aiming for breadth and sensitivity beyond mass-spec workflows for research and precision medicine.

  • Large-scale proteome profiling for drug discovery
  • Biomarker discovery in oncology and neurology research
  • Diagnostics development once platform reaches clinical validation

Key facts

  • Series A led by a16z; Patel and Mallick co-founders (a16z announcement)
  • SPAC merger Jun 2021; NASDAQ ticker NAUT (~$345M gross proceeds per IR)
  • Single-molecule proteomics development stage
  • Sujal Patel previously founded Isilon (EMC acquisition)

Funding history (newest first)

SPAC merger (NASDAQ: NAUT)

2021-06 ~$345M gross proceeds

Source: https://investors.nautilusbio.com/news-releases/news-release-details/nautilus-biotechnology-announces-closing-business-combination

Series A

2018 Not fully disclosed

Source: https://a16z.com/announcement/investing-in-nautilus-biotechnology/

Investors in our directory

Funds linked from Nautilus Biotechnology's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz

Competitive landscape

Edge: Single-molecule approach with experienced infrastructure founder (Patel) and computational biology leadership (Mallick)—a16z board involvement at Series A.

Proteomics tools face long validation cycles and capital intensity. Nautilus went public early via SPAC—trading liquidity without proven commercial revenue creates public-market scrutiny typical of pre-revenue life-science platforms.

  • Seer (Proteograph) direct

    Proteomics platform company; public biotech peer.

  • Mass spectrometry vendors (Thermo, SCIEX) incumbent

    Dominant proteomics tools; Nautilus bets on new modality.

  • Olink / SomaLogic adjacent

    Protein measurement at scale via different chemistries.

Notable stories

  • Patel returned to build biotech infrastructure after Isilon scale-up and EMC sale (a16z narrative).
  • SPAC route reflected 2021 biotech funding window for platform stories pre-revenue.
  • Company aims at proteome-wide measurement—'genomics for proteins' positioning in investor materials.

Industries

Biotech & Life Sciences Healthtech Deep Tech

Related funding articles

Venture Capital Tracker pieces that cover Nautilus Biotechnology's financing or category context.

FAQs about Nautilus Biotechnology

Practical answers founders, operators, and investors typically search for.

Nautilus is developing a single-molecule proteomics platform to measure proteins at scale for research and diagnostics.
NASDAQ: NAUT since June 2021 SPAC merger.
Andreessen Horowitz (/fund/andreessen-horowitz) led the Series A and joined the board.
Sujal Patel (Isilon founder) and Dr. Parag Mallick.
Via SPAC merger with ARYA Sciences Acquisition Corp III in June 2021.
Nautilus bets on single-molecule hardware vs incumbent mass-spec proteomics workflows.
Pre-revenue development-stage public company—check latest SEC filings for current financials.
Seattle, Washington.
Measuring individual protein molecules for sensitivity and breadth—Nautilus's core technical thesis.
Approximately $345M gross proceeds cited in company IR at merger close.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.